<DOC>
	<DOCNO>NCT00168012</DOCNO>
	<brief_summary>The purpose study demonstrate effect IVIG-F10 prevention serious bacterial infection patient primary immunodeficiency . As secondary endpoint rate overall infection , tolerability safety IVIG-F10 study .</brief_summary>
	<brief_title>Efficacy Safety Intravenous Immunoglobulin IVIG-F10 Patients With Primary Immunodeficiencies ( PID )</brief_title>
	<detailed_description />
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Agammaglobulinemia</mesh_term>
	<mesh_term>Common Variable Immunodeficiency</mesh_term>
	<mesh_term>IgG Deficiency</mesh_term>
	<mesh_term>Immunoglobulins , Intravenous</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>Key Patients primary immunodeficiency Regular IVIG therapy least 6 month prior receive IVIGF10 Key Allergic reaction immunoglobulins blood product Steroids ( oral parenteral , daily â‰¥0.15 mg prednisone equivalent/kg/day History cardiac insufficiency Epilepsia</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>Immunoglobulin intravenous</keyword>
	<keyword>Agammaglobulinemia</keyword>
	<keyword>Hypogammaglobulinemia</keyword>
	<keyword>Common variable immunodeficiency</keyword>
	<keyword>Immunoglobulin G</keyword>
	<keyword>Children</keyword>
</DOC>